NYSE : TEVA

Teva Pharmaceutical Industries Limited

$30.81 USD

-$0.37 (-1.19%)

Volume
2.74M
Average Volume
6.31M
Market Capitalization
$35.88B
P/E Ratio
22.77
Dividend Yield
0.00%
Price Target
$41.00
Year High
$37.35
Year Low
$14.99
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.01
Company Overview

NYSE

Richard D. Francis

Drug Manufacturers - Specialty & Generic

Healthcare

TEVA

37000

IL

USD

https://www.tevapharm.com

972 3 914 8213

881624209

0000818686

Liquidity Metrics

2.05

1.01

0.78

0.28

0.00

Sales & Valuation

$17.26B

2.10

4.37

19.33

1.64

Profitability

$1.2

$1.41B

9.03%

7.92%

20.79%

3.90%

P/E Metrics

22.77

0.01

0.01

Analyst Price Target & Rating

$41.00

$42.00

$40.00

Neutral

3/5

46 Analysts

-24.85%

Financial Health Scores

0.84

7/9

$178M

$40.04B

$31.81B

$2.27B

Key Metrics (TTM)

$49.83B

2.86

14.96

1.01

20.79%

11.17%

4.34%

5.18%

$14.84

97 days

Company Executives
Name Title
Evan Lippman Executive Vice President of Business Development
Richard Francis President, Chief Executive Officer & Director
Christine Fox Executive VP of US Commercial & Head of Innovative Franchise
Eric A. Hughes Executive Vice President of Global R&D and Chief Medical Officer
Amir Weiss Senior Vice President & Chief Accounting Officer
Christopher J. Stevo Senior Vice President of Investor Relations & Competitive Intelligence
Kathleen Veit Senior Vice President, Global Compliance & Ethics Officer
Matthew Shields Executive Vice President of Global Operations
Brian Savage Interim Chief Legal Officer
Eliyahu Sharon Kalif Executive Vice President & Chief Financial Officer
Poll Results

No votes yet today — be the first to share your view!

About Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In t ... he central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.

Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.

2026-07-26 14:45:00

Teva's pivot toward branded drugs is benefiting the company's underlying performance and its stock price. While shares have pulled back recently, another big catalyst could play out in the years ahead.

Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.

2026-07-26 09:45:00

Teva's business is shifting away from generic drugs toward branded drugs. Operating margins could soar through next year, boosting earnings potential.

Bank of New York Mellon Corp Decreases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

2026-07-24 03:58:28

Bank of New York Mellon Corp cut its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 2.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,794,432 shares of the company's stock after selling 37,310 shares during the quarter.

Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply

2026-07-22 09:16:35

Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details remain unclear.

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?

2026-07-16 09:46:01

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study

2026-07-12 18:02:15

Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

2026-07-09 12:12:04

Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growth innovative assets.

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

2026-07-09 09:00:00

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG tod

Frequently Asked Questions

What is the current Teva Pharmaceutical Industries Limited (TEVA) stock price?

Teva Pharmaceutical Industries Limited(NYSE:TEVA) stock price is $30.81 in the last trading session. During the trading session, TEVA stock reached the peak price of $37.35 while $14.99 was the lowest point it dropped to. The percentage change in TEVA stock occurred in the recent session was --1.19% while the dollar amount for the price change in TEVA stock was -$0.37.

TEVA's industry and sector of operation?

The NYSE listed TEVA is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of TEVA?

Evan Lippman | Executive Vice President of Business Development
Richard Francis | President, Chief Executive Officer & Director
Christine Fox | Executive VP of US Commercial & Head of Innovative Franchise
Eric A. Hughes | Executive Vice President of Global R&D and Chief Medical Officer
Amir Weiss | Senior Vice President & Chief Accounting Officer

How many employees does TEVA have?

Number of TEVA employees currently stands at 37000. TEVA operates from 124 Dvora Hanevi'a Street, Tel Aviv, TA 6944020, IL.

Link for TEVA official website?

Official Website of TEVA is: https://www.tevapharm.com

How do I contact TEVA?

TEVA could be contacted at phone #972 3 914 8213 and can also be accessed through its website. TEVA operates from 124 Dvora Hanevi'a Street, Tel Aviv, TA 6944020, IL.

How many shares of TEVA are traded daily?

The average number of TEVA shares traded daily for last 3 months was 6.31M.

What is the market cap of TEVA currently?

The market value of TEVA currently stands at $35.88B with its latest stock price at $30.81